Gavins Felicity, Author at BioPharmaJournal

712 POSTS 0 COMMENTS

I am a senior writer at BP Journal. I am tasked with creating content that provides information about and analyzes financial markets, the economy and all things money-related. I have Master's in Business Administration with major in Finance.

Why Temas Resources Corp could be one of the top mining...

Gavins Felicity - January 21, 2022 0

Allogene Therapeutics Inc. (NASDAQ: ALLO) and Antion Biosciences announce Exclusive Global...

Gavins Felicity - January 20, 2022 0

Berkeley Lights Inc. (NASDAQ: BLI) And Aanika Biosciences Announce Strategic Collaboration

Gavins Felicity - January 20, 2022 0

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) Expects Full Year 2021 Revenue of...

Gavins Felicity - January 19, 2022 0

Theravance Biopharma Inc. (NASDAQ: TBPH) enrolls the first patient in the...

Gavins Felicity - January 19, 2022 0

BioCryst Pharmaceutical Inc. (NASDAQ: BCRX) Enrols First Subject in REDEEM-1 BCX9930...

Gavins Felicity - January 18, 2022 0

Why Temas Resources Corp. Could Become the Biggest Commodities Breakout of...

Gavins Felicity - January 18, 2022 0

Gingko Bioworks (NYSE: DNA) announces interim performance updates with biosecurity revenue...

Gavins Felicity - January 18, 2022 0

Trulieve Cannabis Corp (OTCMKTS:TCNNF) Looks for Fresh Momentum on New Product...

Gavins Felicity - January 17, 2022 0

Evofem Biosciences Inc.’s (NASDAQ: EVFM) Phexxi Access Expanded Under New Guidelines...

Gavins Felicity - January 14, 2022 0

12 3...72 Page 1 of 72

Adagio Therapeutics Inc. (NASDAQ: ADGI) Announces That ADG20 Produced A Neutralizing...

Kate Hudson - January 21, 2022 0

Adagio Therapeutics Inc. (NASDAQ: ADGI) has summarised recent findings that were published in three different publications showing its flagship monoclonal antibody (mAb), ADG20, had...